United Therapeutics Corp
UTH
Company Profile
Business description
United Therapeutics specializes in drug development for pulmonary arterial hypertension, a rare and progressive disease marked by abnormally high blood pressure in the arteries of the lungs. The company's therapies for PAH largely focus on the prostacyclin pathway, and many of its treatments are based on the same molecule, treprostinil. Most of the company's sales are generated within the United States. United Therapeutics also markets a pediatric oncology drug, but its focus largely remains in pulmonary arterial hypertension.
Contact
1000 Spring Street
Silver SpringMD20910
USAT: +1 301 608-9292
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2025
Employees
1,168
Stocks News & Analysis
stocks
Ask the analyst: Is the market underestimating Bapcor?
This moated ASX company's shares are in a prolonged slump. I quizzed our analyst Angus Hewitt on its management, the potential impact of EVs, and more.
stocks
Is our ASX best idea still attractive after shares surge?
Shares rose over 21% following the results.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
---|---|---|---|
All Ordinaries | 8,751.60 | 4.00 | 0.05% |
CAC 40 | 8,006.22 | 33.19 | 0.42% |
DAX 40 | 21,911.74 | 124.74 | 0.57% |
Dow JONES (US) | 44,470.41 | 167.01 | 0.38% |
FTSE 100 | 8,767.80 | 67.27 | 0.77% |
HKSE | 21,417.54 | 104.44 | -0.49% |
NASDAQ | 19,714.27 | 190.87 | 0.98% |
Nikkei 225 | 38,801.17 | 14.15 | 0.04% |
NZX 50 Index | 12,917.45 | 41.10 | 0.32% |
S&P 500 | 6,066.44 | 40.45 | 0.67% |
S&P/ASX 200 | 8,484.00 | 1.20 | 0.01% |
SSE Composite Index | 3,315.53 | 6.64 | -0.20% |